目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Objectives of secondary research
2.1.1.2 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
2.1.2.2 Key objective of primary research
2.2 MARKET ESTIMATION
2.2.1 GLOBAL MARKET ESTIMATION
2.2.1.1 Company revenue analysis (bottom-up approach)
2.2.1.2 Revenue share analysis of Thermo Fisher Scientific Inc.
2.2.1.3 MnM repository analysis
2.2.1.4 Primary interviews
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 EXOSOME RESEARCH MARKET OVERVIEW
4.2 NORTH AMERICA: EXOSOME RESEARCH MARKET, BY APPLICATION AND COUNTRY
4.3 EXOSOME RESEARCH MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing investment in pharmaceutical and life sciences R&D
5.2.1.2 Rising focus on development of cancer therapeutics and diagnostics
5.2.1.3 Growing interest in exosome-based procedures
5.2.2 RESTRAINTS
5.2.2.1 Technical complexity of exosome isolation and characterization
5.2.2.2 Regulatory complications and uncertainty in exosome research
5.2.3 OPPORTUNITIES
5.2.3.1 High investments in emerging economies
5.2.3.2 Growing interest in exosome-based therapeutics
5.2.3.3 Rising demand for personalized medicines
5.2.4 CHALLENGES
5.2.4.1 Lack of standard protocols for exosome manufacturing and development
5.2.4.2 Limited understanding of cargo loading capacity
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.4 PRICING ANALYSIS
5.4.1 INDICATIVE PRICE OF EXOSOME RESEARCH PRODUCTS, BY KEY PLAYER, 2024
5.4.2 INDICATIVE PRICE OF EXOSOME RESEARCH PRODUCTS, BY REGION, 2024
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.7.1 ROLE IN ECOSYSTEM
5.8 TECHNOLOGY ANALYSIS
5.8.1 KEY TECHNOLOGIES
5.8.1.1 Ultracentrifugation
5.8.1.2 Nanoparticle tracking analysis (NTA)
5.8.2 COMPLIMENTARY TECHNOLOGIES
5.8.2.1 Microfluidics
5.8.2.2 Western blotting/ELISA
5.8.3 ADJACENT TECHNOLOGIES
5.8.3.1 Next-generation sequencing
5.8.3.2 Mass spectrometry
5.9 PATENT ANALYSIS
5.9.1 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014-2024
5.9.2 LIST OF KEY PATENTS, 2023-2024
5.10 KEY CONFERENCES & EVENTS, 2025-2026
5.11 REGULATORY ANALYSIS
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11.2 REGULATORY FRAMEWORK
5.11.2.1 North America
5.11.2.1.1 US
5.11.2.1.2 Canada
5.11.2.2 Europe
5.11.2.2.1 Germany
5.11.2.2.2 France
5.11.2.2.3 UK
5.11.2.3 Asia Pacific
5.11.2.3.1 China
5.11.2.3.2 Japan
5.11.2.3.3 India
5.11.2.4 Rest of the World
5.11.2.4.1 Brazil
5.11.2.4.2 Argentina
5.11.2.4.3 Saudi Arabia
5.12 PORTER'S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF SUPPLIERS
5.12.4 BARGAINING POWER OF BUYERS
5.12.5 INTENSITY OF COMPETITIVE RIVALRY
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.13.2 KEY BUYING CRITERIA
5.14 INVESTMENT & FUNDING SCENARIO
5.15 TRADE DATA ANALYSIS
5.15.1 IMPORT DATA FOR HS CODE 3822, 2020-2024
5.15.2 EXPORT DATA FOR HS CODE 3822, 2020-2024
5.16 IMPACT OF AI/GEN AI ON EXOSOME RESEARCH MARKET
5.17 IMPACT OF 2025 US TARIFF ON EXOSOME RESEARCH MARKET
5.17.1 INTRODUCTION
5.17.2 KEY TARIFF RATES
5.17.3 PRICE IMPACT ANALYSIS
5.17.4 IMPACTS ON COUNTRY/REGION
5.17.4.1 North America
5.17.4.1.1 US
5.17.4.2 Europe
5.17.4.3 Asia Pacific
5.17.5 IMPACT ON END-USE INDUSTRIES
5.17.5.1 Academic & research institutes
5.17.5.2 Pharmaceutical & biotechnology companies
5.17.5.3 Hospitals & clinical laboratories

6 EXOSOME RESEARCH MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 KITS & REAGENTS
6.2.1 ANTIBODIES
6.2.1.1 High demand for exosome-based markers for disease detection to propel market growth
6.2.2 ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS
6.2.2.1 Availability of rapid and easy-to-use kits & reagents to ensure sustained demand
6.2.3 OTHER KITS & REAGENTS
6.3 INSTRUMENTS
6.3.1 DEMAND FOR SCALABLE EXOSOME DEVELOPMENT THROUGH HIGH-THROUGHPUT SYSTEMS TO DRIVE GROWTH
6.4 SERVICES
6.4.1 LACK OF IN-HOUSE RESOURCES TO SUPPORT MARKET GROWTH

7 EXOSOME RESEARCH MARKET, BY INDICATION
7.1 INTRODUCTION
7.2 CANCER
7.2.1 LUNG CANCER
7.2.1.1 Increasing demand for advanced diagnostics for lung cancer to propel market growth
7.2.2 BREAST CANCER
7.2.2.1 Increased awareness and focus on better non-invasive diagnosis to aid market growth
7.2.3 PROSTATE CANCER
7.2.3.1 Effectiveness of liquid biopsy in detecting prostate cancer before surgery to support market growth
7.2.4 COLORECTAL CANCER
7.2.4.1 Rising focus on exosome-based research on tumor initiation, progression, chemoresistance, and metastasis to drive market
7.2.5 OTHER CANCERS
7.3 NEURODEGENERATIVE DISEASES
7.3.1 INCREASED APPLICATION OF SALIVARY EXOSOMAL CARGO CONTENT IN DISEASE TREATMENT TO PROPEL MARKET GROWTH
7.4 CARDIOVASCULAR DISEASES
7.4.1 GREATER RESEARCH FOCUS ON EXTRACELLULAR VESICLES TO AUGMENT MARKET GROWTH
7.5 INFECTIOUS DISEASES
7.5.1 POTENTIAL FOR EXOSOMES IN DEVELOPING NOVEL INFECTIOUS DISEASE TREATMENTS TO AID ADOPTION
7.6 OTHER INDICATIONS

8 EXOSOME RESEARCH MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 BIOMARKERS
8.2.1 ABILITY TO MODULATE CELL SIGNALING AND REDUCE NEUROINFLAMMATION TO DRIVE ADOPTION
8.3 VACCINE DEVELOPMENT
8.3.1 NEED FOR COMBATING INFECTIOUS DISEASES TO SPUR ADOPTION OF EXOSOME-BASED VACCINES
8.4 TISSUE REGENERATION
8.4.1 MINIMAL SIDE EFFECTS AND HIGH EFFICACY OF EXOSOMES IN TISSUE REGENERATION TO SUPPORT ADOPTION
8.5 OTHER APPLICATIONS

9 EXOSOME RESEARCH MARKET, BY MANUFACTURING SERVICE
9.1 INTRODUCTION
9.2 STEM CELL-DERIVED EXOSOME MANUFACTURING
9.2.1 INCREASE IN DEMAND FOR MESENCHYMAL STEM CELLS-BASED EXOSOMES IN THERAPEUTICS TO AUGMENT MARKET GROWTH
9.3 DENDRITIC CELL-DERIVED EXOSOME MANUFACTURING
9.3.1 SIGNIFICANT DEVELOPMENTS IN DENDRITIC CELL-BASED EXOSOME IMMUNOTHERAPY TO DRIVE MARKET
9.4 OTHER MANUFACTURING SERVICES

10 EXOSOME RESEARCH MARKET, BY END USER
10.1 INTRODUCTION
10.2 ACADEMIC & RESEARCH INSTITUTES
10.2.1 INCREASING NUMBER OF CANCER AND STEM CELL RESEARCH PROJECTS GLOBALLY TO AUGMENT MARKET GROWTH
10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.3.1 HIGH INVESTMENTS AND RAPID INNOVATIONS IN EXOSOME-BASED DIAGNOSTICS TO AID MARKET GROWTH
10.4 HOSPITALS & CLINICAL TESTING LABORATORIES
10.4.1 RISING ADOPTION OF EXOSOME-BASED ONCOLOGY RESEARCH SOLUTIONS TO PROPEL MARKET GROWTH

11 EXOSOME RESEARCH MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC ANALYSIS FOR NORTH AMERICA
11.2.2 US
11.2.2.1 US to dominate North American exosome research market during study period
11.2.3 CANADA
11.2.3.1 Increasing funding for genome-based medical treatments to support market growth
11.3 EUROPE
11.3.1 MACROECONOMIC ANALYSIS FOR EUROPE
11.3.2 GERMANY
11.3.2.1 Advanced biotechnology sector and developed research facilities to favor market growth
11.3.3 UK
11.3.3.1 Favorable R&D initiatives and advanced life science industry to drive market
11.3.4 FRANCE
11.3.4.1 Increasing collaborations between biotechnology firms and research institutes to propel market growth
11.3.5 ITALY
11.3.5.1 Favorable government policies to propel growth of exosome research
11.3.6 SPAIN
11.3.6.1 Increased focus on pharmaceutical R&D to aid market growth
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC ANALYSIS FOR ASIA PACIFIC
11.4.2 CHINA
11.4.2.1 Favorable government initiatives for development of biotechnology industry to drive market
11.4.3 JAPAN
11.4.3.1 High prevalence of cancer and increased healthcare expenditure to aid market growth
11.4.4 INDIA
11.4.4.1 Increasing number of institutional alliances and growing focus on clinical innovation to support market growth
11.4.5 AUSTRALIA
11.4.5.1 Substantial government funding and innovative applications in regenerative medicines to augment market growth
11.4.6 SOUTH KOREA
11.4.6.1 Favorable government initiatives and routine clinical trials to support market growth
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC ANALYSIS FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 Increased government investments in pharmaceutical R&D to drive market
11.5.3 MEXICO
11.5.3.1 Advancements in regenerative medicines and exosome-based therapies to support market growth
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 MACROECONOMIC ANALYSIS FOR MIDDLE EAST & AFRICA
11.6.2 GCC COUNTRIES
11.6.2.1 Strong focus on local pharmaceutical R&D to fuel market growth
11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN EXOSOME RESEARCH MARKET
12.3 REVENUE ANALYSIS, 2020-2024
12.4 MARKET SHARE ANALYSIS, 2024
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.5.5.1 Company footprint
12.5.5.2 Region footprint
12.5.5.3 Offering footprint
12.5.5.4 Indication footprint
12.5.5.5 Application footprint
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
12.6.5.1 Detailed list of key startups/SMEs
12.6.5.2 Competitive benchmarking of key startups/SME players, by offering and region
12.7 COMPANY VALUATION & FINANCIAL METRICS
12.7.1 FINANCIAL METRICS
12.7.2 COMPANY VALUATION
12.8 BRAND/PRODUCT COMPARISON
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES & APPROVALS
12.9.2 DEALS
12.9.3 EXPANSIONS

13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 THERMO FISHER SCIENTIFIC INC.
13.1.1.1 Business overview
13.1.1.2 Products/Services/Solutions offered
13.1.1.3 Recent developments
13.1.1.3.1 Deals
13.1.1.4 MnM view
13.1.1.4.1 Key strengths
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses & competitive threats
13.1.2 QIAGEN
13.1.2.1 Business overview
13.1.2.2 Products/Services/Solutions offered
13.1.2.3 Recent developments
13.1.2.3.1 Product launches
13.1.2.4 MnM view
13.1.2.4.1 Key strengths
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses & competitive threats
13.1.3 LONZA
13.1.3.1 Business overview
13.1.3.2 Products/Services/Solutions offered
13.1.3.3 Recent developments
13.1.3.3.1 Deals
13.1.3.3.2 Expansions
13.1.3.4 MnM view
13.1.3.4.1 Key strengths
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses & competitive threats
13.1.4 DANAHER
13.1.4.1 Business overview
13.1.4.2 Products/Services/Solutions offered
13.1.4.3 Recent developments
13.1.4.3.1 Product launches
13.1.4.3.2 Deals
13.1.4.4 MnM view
13.1.4.4.1 Key strengths
13.1.4.4.2 Strategic choices
13.1.4.4.3 Weaknesses & competitive threats
13.1.5 BIO-TECHNE
13.1.5.1 Business overview
13.1.5.2 Products/Services/Solutions offered
13.1.5.3 Recent developments
13.1.5.3.1 Product launches
13.1.5.4 MnM view
13.1.5.4.1 Key strengths
13.1.5.4.2 Strategic choices
13.1.5.4.3 Weaknesses & competitive threats
13.1.6 SYSTEM BIOSCIENCES, LLC
13.1.6.1 Business overview
13.1.6.2 Products/Services/Solutions offered
13.1.7 AMSBIO
13.1.7.1 Business overview
13.1.7.2 Products/Services/Solutions offered
13.1.8 ROOSTERBIO, INC.
13.1.8.1 Business overview
13.1.8.2 Products/Services/Solutions offered
13.1.8.3 Recent developments
13.1.8.3.1 Deals
13.1.9 MILTENYI BIOTEC
13.1.9.1 Business overview
13.1.9.2 Products/Services/Solutions offered
13.1.9.3 Recent developments
13.1.9.3.1 Product launches
13.1.10 NORGEN BIOTEK CORP.
13.1.10.1 Business overview
13.1.10.2 Products/Services/Solutions offered
13.1.11 AETHLON MEDICAL, INC.
13.1.11.1 Business overview
13.1.11.2 Products/Services/Solutions offered
13.1.11.3 Recent developments
13.1.11.3.1 Product approvals
13.1.12 CREATIVE MEDICAL TECHNOLOGIES HOLDINGS, INC.
13.1.12.1 Business overview
13.1.12.2 Products/Services/Solutions offered
13.1.13 SPECTRIS
13.1.13.1 Business overview
13.1.13.2 Products/Services/Solutions offered
13.1.13.3 Recent developments
13.1.13.3.1 Product launches
13.1.13.3.2 Deals
13.1.14 NANOFCM, INC.
13.1.14.1 Business overview
13.1.14.2 Products/Services/Solutions offered
13.1.15 IZON SCIENCE LIMITED
13.1.15.1 Business overview
13.1.15.2 Products/Services/Solutions offered
13.1.16 CAPRICOR THERAPEUTICS, INC.
13.1.16.1 Business overview
13.1.16.2 Products/Services/Solutions offered
13.2 OTHER PLAYERS
13.2.1 ANJARIUM BIOSCIENCES AG
13.2.2 CILOA
13.2.3 INNOVAPREP
13.2.4 ILIAS BIOLOGICS INC.
13.2.5 UNCHAINED LABS
13.2.6 RION INC.
13.2.7 CELL GUIDANCE SYSTEM LLC
13.2.8 INOVIQ
13.2.9 NX PHARMAGEN
13.2.10 EXOPHARM
13.2.11 EVERZOM
13.2.12 NANOSOMIX
13.2.13 CREATIVE BIOLABS

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS